RaQualia Pharma Inc. provided consolidated earnings guidance for the fiscal year ending December 31, 2023. For the period, the company expected net sales of JPY 2,799 million, operating profit of JPY 260 million, profit attributable to owners of parent of JPY 183 million and earnings per share of JPY 8.74.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
569 JPY | -3.40% | -4.85% | -17.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.30% | 81.67M | |
+38.35% | 705B | |
+32.82% | 583B | |
-3.70% | 364B | |
+20.08% | 332B | |
+5.01% | 291B | |
+17.16% | 238B | |
-3.76% | 210B | |
+10.46% | 209B | |
+8.55% | 169B |
- Stock Market
- Equities
- 4579 Stock
- News RaQualia Pharma Inc.
- RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023